GOVX
GeoVax Labs IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.69M
P/E Ratio
—
EPS
$-31.75
Beta
3.81
52W High
$34.75
52W Low
$1.15
50-Day MA
$1.93
200-Day MA
$10.78
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
9.65
PEG Ratio
0.00
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a modified vaccinia ankara virus-like particle vaccine platform. The company is headquartered in Smyrna, Georgia.
Fundamentals
| Revenue (TTM) | $3.35M |
| Gross Profit (TTM) | $-19.38M |
| EBITDA | $-25.47M |
| Operating Margin | -762.00% |
| Return on Equity | -377.40% |
| Return on Assets | -178.90% |
| Revenue/Share (TTM) | $5.40 |
| Book Value | $4.13 |
| Price-to-Book | 0.57 |
| Price-to-Sales (TTM) | 0.80 |
| EV/Revenue | 0.406 |
| EV/EBITDA | 15.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 183.50% |
| Shares Outstanding | $2.22M |
| Float | $1.19M |
| % Insiders | 0.16% |
| % Institutions | 10.14% |
Analyst Ratings
Consensus ($270.83 target)
3
Buy1
HoldData last updated: 4/8/2026